Genome Engineering in Accelerating Discovery and Preclinical Applications
Use of Biocytogen’s CRISPR-based Extreme Genome Editing technology improves the efficiency of large fragment knock-in by up to 10-20 fold, meaning we can generate targeted cell lines, mouse and rat models in industry-leading timelines with a 98% success rate.
Read more
4th Annual Next Gen Immuno-Oncology Virtual Congress: Humanized Immune Checkpoint Mice Improve Translatability of Novel Immunotherapies
Biocytogen’s humanized CD3E & CD3EDG models allow for broader targeting of the entire CD3 complex with novel mono- & bispecific antibody therapeutics.
Read more
AET Europe 2021: Powerful Engine for Therapeutic Antibody Discovery – RenMab/RenLite Immunoglobulin Humanized Mouse Platform
Learn more about Biocytogen’s established first and second generation of immunoglobulin humanized mouse platforms: RenMab and RenLite.
Read more
FcRn Therapies 2021 Conference: Humanized Mouse Models to Assess the In Vivo Efficacy of Antibody Therapeutics
Learn about the powerful models of Humanized mouse in IL4/IL4RA and IL-17 mice in various in-vivo settings
Read more
AET Europe 2020: Advancing Therapeutic Antibody discovery using RenMab/RenLite/RenMab KO immunoglobulin humanized mouse platforms
To meet the expanding needs of the therapeutic antibody market, Biocytogen established first and second generation of immunoglobulin humanized mouse platforms: RenMab, RenMab KO and RenLite.
Read more
IO Summit Boston: Improve Translation of Humanized Animal Models for Immunotherapy
Learn about the new developments in humanized animal models to get ideas on how models can be applied to solve specific translational challenges.
Read more
